165 lines
79 KiB
Text
165 lines
79 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548609">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548609/?report=reader">
|
|
<meta name="ncbi_pagename" content="Metronidazole - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Metronidazole - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Metoprolol/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Mexiletine/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Metronidazole">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2020/02/20">
|
|
<meta name="citation_pmid" content="31643921">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548609/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Metronidazole">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2020/02/20">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548609/">
|
|
<meta name="description" content="Metronidazole is a nitroimidazole derivative bactericidal agent widely used in the treatment of many anaerobic and certain protozoan and parasitic infections. Metronidazole has been linked to rare instances of acute, clinically apparent liver injury.">
|
|
<meta name="og:title" content="Metronidazole">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Metronidazole is a nitroimidazole derivative bactericidal agent widely used in the treatment of many anaerobic and certain protozoan and parasitic infections. Metronidazole has been linked to rare instances of acute, clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548609/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Metronidazole/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548609/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E96E47D7DE3F10000000000C500AB.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548609/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Metoprolol/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Metronidazole</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Mexiletine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548609/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548609/&text=Metronidazole"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548609/?report=classic">Switch to classic view</a><a href="/books/NBK548609/pdf/Bookshelf_NBK548609.pdf">PDF (148K)</a><a href="/books/NBK548609/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548609%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E96E47D7DE3F10000000000C500AB.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548609_"><span class="title" itemprop="name">Metronidazole</span></h1><p class="fm-aai"><a href="#_NBK548609_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Metronidazole.OVERVIEW"><h2 id="_Metronidazole_OVERVIEW_">OVERVIEW</h2><div id="Metronidazole.Introduction"><h3>Introduction</h3><p>Metronidazole is a nitroimidazole derivative bactericidal agent widely used in the treatment of many anaerobic and certain protozoan and parasitic infections. Metronidazole has been linked to rare instances of acute, clinically apparent liver injury.</p></div><div id="Metronidazole.Background"><h3>Background</h3><p>Metronidazole (met" roe nid' a zole) is a nitroimidazole antibiotic that is activated by reduction of its nitro group by susceptible organisms. The activated form of metronidazole is a highly reactive radical anion which targets and damages large protein molecules and DNA. Mammalian cells do not ordinarily activate metronidazole, which accounts for its lack of toxicity in humans. Metronidazole was approved for use in the United States in 1963 and currently several million prescriptions are filled yearly. Metronidazole is indicated for treatment and prophylaxis of infections with susceptible anaerobic bacteria and protozoa. It is used frequently in combination with other antibiotics, proton pump inhibitors and bismuth as therapy of <i>Helicobacter pylori</i> infection. The recommended dosage is 500 to 750 mg taken orally three times daily for 5 to 10 days. Metronidazole is available alone in tablets of 250, 375, 500 and 750 mg as well as in combination with other medications, in multiple generic formulations and under several brand names including Flagyl, Metryl, Noritate, Pylera and Helida. Other formulations include injectable solutions, extended release tablets, suppositories, and topical creams. The most common side effects include metallic taste, nausea, vomiting, abdominal discomfort and diarrhea. Uncommon but potentially severe adverse events include seizures, neuropathy and encephalopathy, hypersensitivity reactions and Stevens-Johnson syndrome. Metronidazole has been found to be carcinogenic in rats and mice and long term and unwarranted use should be avoided.</p></div><div id="Metronidazole.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Despite the wide use of metronidazole, only rare cases of hepatotoxicity have been reported, and metronidazole is not listed among causes of drug induced liver injury and acute liver failure in large case series. High doses of metronidazole given parenterally or in an overdose can cause elevations in serum aminotransferase levels, but these are usually self-limited and minimally symptomatic (Case 1). Acute, clinically apparent liver injury from metronidazole is rare. Ornidazole, another synthetic nitroimidazole that was available in Europe, was implicated in several cases of drug induced liver injury, with a latency of a few days or weeks and a hepatocellular pattern of injury. Metronidazole has been associated with a similar acute hepatitis-like syndrome with a short incubation period, but much more rarely. Fever, rash and eosinophilia are uncommon as are autoimmune features. A fatal recurrence of acute liver injury after reexposure to metronidazole has been published (Case 2). Strikingly, multiple instances of metronidazole hepatoxicity have been reported in the rare genetic disease, Cockayne syndrome in which there is an absence or deficiency in an important DNA repair enzyme responsible for nucleotide excision repair. The cases were marked by a short latency (1 to 7 days) to onset of jaundice, a hepatocellular pattern of enzyme elevations and severe course with a high mortality rate. Whether patients with Cockayne syndrome have a similar high risk for severe hepatitis with other nitroimidazoles (such as tinidazole) is not known.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Metronidazole.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of acute liver injury due to metronidazole is probably immunoallergic, given the short latency period and recurrence with rechallenge. However, the frequency of severe hepatotoxicity in children with Cockayne syndrome suggests a direct toxic effect, probably involving breaks in double stranded DNA. Metronidazole is extensively metabolized in the liver and has multiple drug-drug interactions with agents that induce or inhibit cytochrome P450 enzymes (particularly CYP 3A4).</p></div><div id="Metronidazole.Outcome_and_Management"><h3>Outcome and Management</h3><p>The liver injury from metronidazole is rare, but can result in liver failure and death. In typical cases, recovery is expected in 1 to 3 months. Rechallenge results in prompt recurrence and should be avoided. Patients with Cockayne syndrome should not receive metronidazole and should best avoid other nitroimidazole antibiotics such as tinidazole.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/?report=reader">Antiinfective Agents</a>; Gastrointestinal Agents</p><p>Other Drugs in the Subclass, Nitroimidazoles: <a href="/books/n/livertox/Benznidazole/?report=reader">Benznidazole</a>, <a href="/books/n/livertox/Secnidazole/?report=reader">Secnidazole</a>, <a href="/books/n/livertox/Tinidazole/?report=reader">Tinidazole</a></p></div></div><div id="Metronidazole.CASE_REPORTS"><h2 id="_Metronidazole_CASE_REPORTS_">CASE REPORTS</h2><div id="Metronidazole.Case_1_Elevations_in_serum"><h3>Case 1. Elevations in serum aminotransferase levels during intravenous metronidazole therapy.(<a class="bibr" href="#Metronidazole.REF.1" rid="Metronidazole.REF.1">1</a>)</h3><p>A 58 year old man underwent prostate biopsy and cystoscopy and 32 hours later developed fever and was admitted for treatment of suspected urosepsis. After a combination of cephalosporin and tobramycin failed to affect his course, intravenous metronidazole (500 mg every 6 hours) was added. He had rapid clinical improvement, but then complained of abdominal pain, nausea, headache and a metallic taste. Metronidazole was stopped after 5 days and he was switched on oral cefaclor. At the same time, serum ALT and alkaline phosphatase levels were found to be elevated. Physical examination showed slight hepatomegaly without jaundice. Hepatitis B serology was negative. Over the following week, the patient recovered symptomatically and was discharged home. All laboratory tests were normal 4 weeks after stopping metronidazole.</p><div id="Metronidazole.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetronidazoleTc"><a href="/books/NBK548609/table/Metronidazole.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetronidazoleTc" rid-ob="figobMetronidazoleTc"><img class="small-thumb" src="/books/NBK548609/table/Metronidazole.Tc/?report=thumb" src-large="/books/NBK548609/table/Metronidazole.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metronidazole.Tc"><a href="/books/NBK548609/table/Metronidazole.Tc/?report=objectonly" target="object" rid-ob="figobMetronidazoleTc">Table</a></h4></div></div></div><div id="Metronidazole.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetronidazoleTd"><a href="/books/NBK548609/table/Metronidazole.Td/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetronidazoleTd" rid-ob="figobMetronidazoleTd"><img class="small-thumb" src="/books/NBK548609/table/Metronidazole.Td/?report=thumb" src-large="/books/NBK548609/table/Metronidazole.Td/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metronidazole.Td"><a href="/books/NBK548609/table/Metronidazole.Td/?report=objectonly" target="object" rid-ob="figobMetronidazoleTd">Table</a></h4></div></div></div><div id="Metronidazole.Comment"><h4>Comment</h4><p>The serum enzyme elevations were compatible with mild metronidazole hepatotoxicity, given the short latency period and rapid recovery after stopping. The rapid onset and rapid recovery after high doses of intravenous metronidazole suggest direct hepatic injury. However, idiosyncratic cases are also marked by short latency period and rechallenge, even with oral metronidazole should be avoided.</p></div></div><div id="Metronidazole.Case_2_Acute_hepatocellula"><h3>Case 2. Acute hepatocellular injury due to metronidazole with fatal recurrence on reexposure.(<a class="bibr" href="#Metronidazole.REF.2" rid="Metronidazole.REF.2">2</a>)</h3><p>A 24 year old woman was treated with metronidazole for Clostridium difficile infection after a course of penicillin for a tooth abscess. Her diarrhea improved, but a few days later she developed nausea and vomiting followed by jaundice. Her past medical history included asthma and frequent upper respiratory infections. Laboratory tests showed total bilirubin of 7.9 mg/dL with marked elevations in serum aminotransferase levels, but modest increase in alkaline phosphatase (Table). Tests for hepatitis A, B and C and for autoantibodies were negative. An ultrasound showed no evidence of biliary obstruction. Metronidazole was discontinued and she began to improve, but her recovery was slow and symptoms persisted for at least two months and laboratory tests did not return to normal for at least nine months. Two years later, she was treated for bacterial vaginitis with metronidazole and tetracycline and one week later developed nausea, vomiting and jaundice. Serum bilirubin was 12.2 mg/dL, ALT and AST were more than 100 fold elevated, and prothrombin index was <9%. She was transferred to a liver transplant center where she developed progressive hepatic coma. Tests for hepatitis A, B and C were again negative. She underwent liver transplantation, but died in the perioperative period. Explant showed massive hepatic necrosis and cholestasis.</p><div id="Metronidazole.Key_Points_1"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetronidazoleTe"><a href="/books/NBK548609/table/Metronidazole.Te/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetronidazoleTe" rid-ob="figobMetronidazoleTe"><img class="small-thumb" src="/books/NBK548609/table/Metronidazole.Te/?report=thumb" src-large="/books/NBK548609/table/Metronidazole.Te/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metronidazole.Te"><a href="/books/NBK548609/table/Metronidazole.Te/?report=objectonly" target="object" rid-ob="figobMetronidazoleTe">Table</a></h4></div></div></div><div id="Metronidazole.Laboratory_Values_1"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetronidazoleTf"><a href="/books/NBK548609/table/Metronidazole.Tf/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetronidazoleTf" rid-ob="figobMetronidazoleTf"><img class="small-thumb" src="/books/NBK548609/table/Metronidazole.Tf/?report=thumb" src-large="/books/NBK548609/table/Metronidazole.Tf/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metronidazole.Tf"><a href="/books/NBK548609/table/Metronidazole.Tf/?report=objectonly" target="object" rid-ob="figobMetronidazoleTf">Table</a></h4></div></div></div><div id="Metronidazole.Comment_1"><h4>Comment</h4><p>Severe acute hepatocellular injury from a short course of metronidazole with slow recovery, followed by a rapid and fatal recurrence on reexposure.</p></div></div></div><div id="Metronidazole.PRODUCT_INFORMATION"><h2 id="_Metronidazole_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Metronidazole – Generic, Flagyl®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antiinfective Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=metronidazole" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Metronidazole.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Metronidazole_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetronidazoleTg"><a href="/books/NBK548609/table/Metronidazole.Tg/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetronidazoleTg" rid-ob="figobMetronidazoleTg"><img class="small-thumb" src="/books/NBK548609/table/Metronidazole.Tg/?report=thumb" src-large="/books/NBK548609/table/Metronidazole.Tg/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metronidazole.Tg"><a href="/books/NBK548609/table/Metronidazole.Tg/?report=objectonly" target="object" rid-ob="figobMetronidazoleTg">Table</a></h4></div></div></div><div id="Metronidazole.CITED_REFERENCES"><h2 id="_Metronidazole_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="Metronidazole.REF.1">Appleby DH, Vogtland HD. Suspected metronidazole hepatotoxicity. <span><span class="ref-journal">Clin Pharm. </span>1983;<span class="ref-vol">2</span>:373–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6883967" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6883967</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="Metronidazole.REF.2">Björnsson E, Nordlinder H, Olsson R. Metronidazol as a probable cause of severe liver injury. <span><span class="ref-journal">Hepatogastroenterology. </span>2002;<span class="ref-vol">49</span>:252–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11941968" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11941968</span></a>]</div></dd></dl></dl></div><div id="Metronidazole.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Metronidazole_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 February 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Metronidazole.REF.zimmerman.1999">Zimmerman HJ. Amebicides. Hepatic injury from antimicrobial agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, p. 592.<div><i>(Expert review of liver injury published in 1999 mentions that metronidazole has only rarely been incriminated in causing liver injury).</i></div></div></li><li><div class="bk_ref" id="Metronidazole.REF.moseley.2013">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 463-82.<div><i>(Review of hepatotoxicity of antibiotics; does not discuss metronidazole).</i></div></div></li><li><div class="bk_ref" id="Metronidazole.REF.wetzel">Wetzel DM, Phillips MA. Chemotherapy of protozoal infections. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 20181, pp. 987-1000.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Metronidazole.REF.fagin.1965.1128">Fagin ID. Jaundice associated with metronidazole. Letter to editor. <span><span class="ref-journal">JAMA. </span>1965;<span class="ref-vol">193</span>:1128.</span><div>
|
|
<i>(46 year old man developed fever after 4 days of metronidazole [250 mg/day] and he was given an injection of penicillin; 6 days later, he developed jaundice [bilirubin 5.4 mg/dL, AST 143 U/L, Alk P 1.5 times ULN], resolving in 2 months).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.bonfiglio.1967.249">Bonfiglio G, Donadio G. Results of the clinical testing of a new drug metronidazole in the treatment of chronic alcoholism. <span><span class="ref-journal">Br J Addict. </span>1967;<span class="ref-vol">62</span>:249–55.</span><div>
|
|
<i>(Open label trial of metronidazole [750 mg daily] in 60 patients with alcoholism for up to 45 days, most patients had flushing response to alcohol; no mention of hepatotoxicity or ALT elevations).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF8">Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra-abdominal infection. <span><span class="ref-journal">Surgery. </span>1983;<span class="ref-vol">93</span>(1 Pt 2):221–9.</span> [No authors listed] [<a href="https://pubmed.ncbi.nlm.nih.gov/6849209" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6849209</span></a>]<div>
|
|
<i>(Multicenter study comparing clindamycin to metronidazole in 186 patients with severe infections; similar efficacy, AST elevations in 18% on metronidazole vs 10% on clindamycin, but no frank hepatitis or discontinuation for liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.appleby.1983.373">Appleby DH, Vogtland HD. Suspected metronidazole hepatotoxicity. <span><span class="ref-journal">Clin Pharm. </span>1983;<span class="ref-vol">2</span>:373–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6883967" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6883967</span></a>]<div>
|
|
<i>(58 year old man with urosepsis developed ALT [735 U/L] and Alk P [238 U/L] elevations without jaundice after 4 days of iv metronidazole, resolving in 1 week; also received tobramycin and cefapirin: Case 1).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.uchihara.1984.1612">Uchihara M, Maeda M, Koyama W, Sakamoto S, Kanayama M. A case of metronidazole-induced liver injury. <span><span class="ref-journal">Acta Hepatol Jpn. </span>1984;<span class="ref-vol">25</span>:1612–5.</span><div>
|
|
<i>(35 year old man developed fever, abdominal discomfort, eosinophilia and enzymes elevations [bilirubin 1.6 mg/dL, ALT 478 U/L, Alk P 469 U/L] after 2 weeks of oral metronidazole, with positive lymphocyte stimulation test, recovery in 4 weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.smilack.1991.1270">Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. <span><span class="ref-journal">Mayo Clin Proc. </span>1991;<span class="ref-vol">66</span>:1270–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1749296" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1749296</span></a>]<div>
|
|
<i>(Review of uses and toxicities of antibiotics; no mention of hepatotoxicity of metronidazole).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.hestin.1994.286">Hestin D, Hanesse B, Frimat L, Trechot P, Netter P, Kessler M. Metronidazole-associated hepatotoxicity in a hemodialyzed patient. <span><span class="ref-journal">Nephron. </span>1994;<span class="ref-vol">68</span>:286.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7830880" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7830880</span></a>]<div>
|
|
<i>(68 year old woman developed nausea and right upper quadrant pain after 1 week of oral metronidazole therapy; ALT 650 U/L but no jaundice, resolved within 15 days of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.lam.1995.803">Lam S, Bank S. Hepatotoxicity caused by metronidazole overdose. <span><span class="ref-journal">Ann Intern Med. </span>1995;<span class="ref-vol">122</span>:803.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7717611" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7717611</span></a>]<div>
|
|
<i>(58 year old woman took an overdose of metronidazole ~12.5 g and developed asymptomatic rise in ALT [to 2570 U/L], AST [6120 U/L], but minimal increase in Alk P [95 U/L] and bilirubin [2.1 mg/dL], levels peaking 2-3 days after overdose and resolving to normal within 4 weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.ko_ar.2001.737">Koşar Y, Sasmaz N, Oguz P, Kacar S, Erden E, Parlak E, Akdogan M. Ornidazole-induced autoimmune hepatitis. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2001;<span class="ref-vol">13</span>:737–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11434605" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11434605</span></a>]<div>
|
|
<i>(35 year old woman developed jaundice within a few days of starting oral ornidazole [bilirubin 17 mg/dL, ALT 1140 U/L, Alk P 145 U/L, SMA 1:1280], responding to corticosteroids with no relapse when therapy was stopped, but she was then retreated with ornidazole and promptly redeveloped a similar clinical picture with rise in SMA from 1:80 to 1:1280).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.bj_rnsson.2002.252">Björnsson E, Nordlinder H, Olsson R. Metronidazol as a probable cause of severe liver injury. <span><span class="ref-journal">Hepatogastroenterology. </span>2002;<span class="ref-vol">49</span>:252–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11941968" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11941968</span></a>]<div>
|
|
<i>(24 year old woman treated with metronidazole for pseudomembranous colitis developed symptoms and jaundice a few days later with progression to acute hepatitis [bilirubin 7.9 mg/dL, ALT 100 times ULN, Alk P 2 times ULN], with slow and incomplete recovery, and relapse and acute liver failure with retreatment with metronidazole 2 years later, the explant showing massive necrosis: Case 2).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.tabak.2003.351">Tabak F, Ozaras R, Erzin Y, Celik AF, Ozbay G, Senturk H. Ornidazole-induced liver damage: report of three cases and review of the literature. <span><span class="ref-journal">Liver Int. </span>2003;<span class="ref-vol">23</span>:351–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14708896" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14708896</span></a>]<div>
|
|
<i>(Ornidazole, a nitroimidazole derivative similar to metronidazole, was linked to 3 cases of acute hepatitis in women ages 25-50 years, arising after 3-4 days of therapy with ALT 977, 3042 and 1160 U/L; Alk P 1062, 422 and 431 U/L; bilirubin 32, 48 and 10 mg/dL, resolving in 1-2 months, no autoantibodies or allergic findings; 6 cases in literature, 4 icteric, 1 fatal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.orion.2005.182">Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. <span><span class="ref-journal">Clin Dermatol. </span>2005;<span class="ref-vol">23</span>:182–92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15802212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15802212</span></a>]<div>
|
|
<i>(Review of serious complications of medications of skin disorders, mentions hepatotoxicity of metronidazole briefly).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
|
<i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, no case was attributed to metronidazole).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.hussein.2011.44">Hussein R, El-Halabi M, Ghaith O, Jurdi N, Azar C, Mansour N, Sharara AI. Severe hepatotoxicity associated with the combination of spiramycin plus metronidazole. <span><span class="ref-journal">Arab J Gastroenterol. </span>2011;<span class="ref-vol">12</span>:44–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21429456" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21429456</span></a>]<div>
|
|
<i>(Three men, ages 22 to 41 years, developed jaundice “a few weeks” to 2 months after treatment with a fixed combination of spiramycin and metronidazole [Rodogyl] for dental infections [bilirubin 28, 8.0 and 11.3 rising to 24 mg/dL, ALT 210, 1900 and 188 U/L, Alk P 109 and 344 U/L], one recovering spontaneously, one treated with prednisone and one undergoing emergency liver transplantation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.abdel_ghaffar.2011.13">Abdel Ghaffar TY, Elsobky ES, Elsayed SM. Cholestasis in patients with Cockayne syndrome and suggested modified criteria for clinical diagnosis. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2011;<span class="ref-vol">6</span>:13.</span> [<a href="/pmc/articles/PMC3083330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3083330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21477313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21477313</span></a>]<div>
|
|
<i>(Among 9 patients with Cockayne syndrome followed at a single Egyptian referral center, 7 had at least one episode of transient liver injury, 4 with jaundice and 2 resulting in death, often following bacterial infections, an anesthetic agent being implicated in one instance).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.kancherla.2013.568193">Kancherla D, Gajendran M, Vallabhaneni P, Vipperla K. Metronidazole induced liver injury: a rare immune mediated drug reaction. <span><span class="ref-journal">Case Rep Gastrointest Med. </span>2013;<span class="ref-vol">2013</span>:568193. </span> [<a href="/pmc/articles/PMC3884854/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3884854</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24455335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24455335</span></a>]<div>
|
|
<i>(54 year old man developed jaundice a few weeks after a 2 week course of metronidazole for Clostridium difficile associated diarrhea [bilirubin 7.2 mg/dL, ALT 973 U/L, Alk P 96 U/L, INR 1.9], with a severe and prolonged course, corticosteroid therapy, but eventual recovery).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
|
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none of the 96 were attributed to metronidazole).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.chalasani.2015">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to metronidazole).</i></div></div></li><li><div class="bk_ref" id="Metronidazole.REF.wilson.2015.e706">Wilson BT, Strong A, O'Kelly S, Munkley J, Stark Z. Metronidazole toxicity in Cockayne syndrome: a case series. <span><span class="ref-journal">Pediatrics. </span>2015;<span class="ref-vol">136</span>:e706–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26304821" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26304821</span></a>]<div>
|
|
<i>(Case series of 4 patients [ages 1-21 years; 3 girls, 1 boy] with Cockayne syndrome who developed jaundice and severe liver injury within 1-7 days of starting metronidazole usually in high doses [initial bilirubin 1.9-7.5 mg/dL, ALT 544-6206 U/L, Alk P 273-848 U/L, INR 1.4->10], 3 dying and 1 surviving after a prolonged course).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.blumenthal.2015">Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP, Nelson SB. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol 2015; 136: 1288-94. e1. [<a href="/pmc/articles/PMC4640981/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4640981</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25981739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25981739</span></a>]<div><i>(Among 824 patients receiving outpatient parenteral antibiotic therapy who had concurrent white blood cell and differential counts, eosinophilia [>500 cells/uL] was found in 25%, being most common with vancomycin [30%], the penicillins [28%], carbapenems [28%], cephalosporins [22%], fluoroquinolones [21%], and less common with metronidazole [15%] and there was no association of eosinophilia with liver test abnormalities).</i></div></div></li><li><div class="bk_ref" id="Metronidazole.REF.mazuski.2016.1380">Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. <span><span class="ref-journal">Clin Infect Dis. </span>2016;<span class="ref-vol">62</span>:1380–9.</span> [<a href="/pmc/articles/PMC4872289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26962078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26962078</span></a>]<div>
|
|
<i>(In a randomized trial of ceftazidime/avibactam and metronidazole vs meropenem only for complicated intra-abdominal infections, cure rates were similar for the two regimens [82% vs 85%] as were adverse events including “liver disorders” of 2.1% vs 1.5%).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF27">Drugs for Helicobacter pylori infection. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2017;<span class="ref-vol">59</span>(1525):113–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28699931" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28699931</span></a>]<div>
|
|
<i>(Concise review of the efficacy, safety and costs of drugs for H. pylori infection lists preferred regimens, usually includes metronidazole [500 mg twice daily for 10-14 days] whose adverse effects can include metallic taste, reactions to alcohol, seizures and neuropathy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.zhao.2017.e8009">Zhao Z, Bao L, Yu X, Zhu C, Xu J, Wang Y, Yin M, et al. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report. <span><span class="ref-journal">Medicine (Baltimore). </span>2017;<span class="ref-vol">96</span>:e8009. </span> [<a href="/pmc/articles/PMC6392967/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6392967</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28885366" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28885366</span></a>]<div>
|
|
<i>(29 year old woman developed progressive, severe cholestasis and bile duct loss attributed to a 4-5 day course of antibiotics, reportedly “a cephalosporin”, metronidazole and clotrimazole).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.pandey.2018.196">Pandey S, Gupta GK, Wanjari SJ, Nijhawan S. Comparative study of tinidazole versus metronidazole in treatment of amebic liver abscess: A randomized control trial. <span><span class="ref-journal">Indian J Gastroenterol. </span>2018;<span class="ref-vol">37</span>:196–201.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29948994" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29948994</span></a>]<div>
|
|
<i>(Among 150 patients with amebic liver abscess treated with metronidazole [14 days] or tinidazole [5 days], time to response was better with tinidazole but ultimate response rates were similar, although metronidazole was associated with a higher rate of adverse events including nausea, vomiting and metallic taste resulting in early discontinuation in 10%; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.shamberg.2018.674">Shamberg L, Vaziri H. Hepatotoxicity of inflammatory bowel disease medications. <span><span class="ref-journal">J Clin Gastroenterol. </span>2018;<span class="ref-vol">52</span>:674–84.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30036242" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30036242</span></a>]<div>
|
|
<i>(Review of the hepatotoxicity of drugs used for inflammatory bowel disease mentions that metronidazole has been reported to cause liver injury but it is rare and does not justify prospective monitoring during therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metronidazole.REF.ataee.2020.9634196">Ataee P, Karimi A, Eftekhari K. Hepatic failure following metronidazole in children with Cockayne syndrome. <span><span class="ref-journal">Case Rep Pediatr. </span>2020;<span class="ref-vol">2020</span>:9634196. </span> [<a href="/pmc/articles/PMC7008298/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7008298</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32082677" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32082677</span></a>]<div>
|
|
<i>(Two cases: 2 and 5 years old boys with type B [infant onset] Cockayne syndrome developed jaundice, vomiting and agitation 2 and 3 days after starting oral metronidazole for minor infection [bilirubin 13.7 and 16.0 mg/dL, ALT 2815 and 2248 U/L, Alk P 1265 and 1654 U/L, INR 5.1 and 4.6], one dying within 2 days of admission and the second recovering but with persistent jaundice and serum enzyme elevations one month later).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548609_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">February 20, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Metronidazole. [Updated 2020 Feb 20].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Metoprolol/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Mexiletine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobMetronidazoleTc"><div id="Metronidazole.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548609/table/Metronidazole.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metronidazole.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Metronidazole.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Metronidazole.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metronidazole, 500 mg iv every 6 hours for 5 days</td></tr><tr><th id="hd_b_Metronidazole.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Metronidazole.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=10)</td></tr><tr><th id="hd_b_Metronidazole.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Metronidazole.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ (ALT elevations without jaundice)</td></tr><tr><th id="hd_b_Metronidazole.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_Metronidazole.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td></tr><tr><th id="hd_b_Metronidazole.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Metronidazole.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 days after stopping</td></tr><tr><th id="hd_b_Metronidazole.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Metronidazole.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cefaclor, tobramycin</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetronidazoleTd"><div id="Metronidazole.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548609/table/Metronidazole.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metronidazole.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Metronidazole.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Metronidazole.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Metronidazole.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT<br />(U/L)</th><th id="hd_h_Metronidazole.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Metronidazole.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin<br />(mg/dL)</th><th id="hd_h_Metronidazole.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">65</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Prostate biopsy, cystoscopy</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Fever 104 <sup>o</sup>F: cefapirin, tobramycin</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_3 hd_h_Metronidazole.Td_1_1_1_4 hd_h_Metronidazole.Td_1_1_1_5" colspan="3" rowspan="1" style="text-align:center;vertical-align:top;">Start iv metronidazole</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Continued fever</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metronidazole.Td_1_1_1_3 hd_h_Metronidazole.Td_1_1_1_4 hd_h_Metronidazole.Td_1_1_1_5" colspan="3" rowspan="1" style="text-align:center;vertical-align:top;">Stop metronidazole</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Started cefaclor</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">720</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">200</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">GGT 459</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">238</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.5</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">464</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">191</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.9</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">319</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">167</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">71</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Discharged</td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td><td headers="hd_h_Metronidazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 days</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">42</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Td_1_1_1_1 hd_h_Metronidazole.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Metronidazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><42</b>
|
|
</td><td headers="hd_h_Metronidazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><115</b>
|
|
</td><td headers="hd_h_Metronidazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Metronidazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetronidazoleTe"><div id="Metronidazole.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548609/table/Metronidazole.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metronidazole.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Metronidazole.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Metronidazole.Te_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metronidazole (dose and duration not given)</td></tr><tr><th id="hd_b_Metronidazole.Te_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Metronidazole.Te_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=62)</td></tr><tr><th id="hd_b_Metronidazole.Te_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Metronidazole.Te_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ initially (jaundice and hospitalization)<br /> 5+ on reexposure (liver transplantation, death)</td></tr><tr><th id="hd_b_Metronidazole.Te_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_Metronidazole.Te_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">~5-10 days</td></tr><tr><th id="hd_b_Metronidazole.Te_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Metronidazole.Te_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 months after initial exposure</td></tr><tr><th id="hd_b_Metronidazole.Te_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Metronidazole.Te_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral tetracycline</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetronidazoleTf"><div id="Metronidazole.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548609/table/Metronidazole.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metronidazole.Tf_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Metronidazole.Tf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Metronidazole.Tf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Metronidazole.Tf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT*<br />(U/L)</th><th id="hd_h_Metronidazole.Tf_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Metronidazole.Tf_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin<br />(mg/dL)</th><th id="hd_h_Metronidazole.Tf_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Tf_1_1_1_3 hd_h_Metronidazole.Tf_1_1_1_4 hd_h_Metronidazole.Tf_1_1_1_5 hd_h_Metronidazole.Tf_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Metronidazole given for C difficile</td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">~10 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5282</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">606</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.9</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3000</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">500</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20.1</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 mo</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 mo</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">104</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">450</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10.5</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5 mos</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5 mos</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">102</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">492</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 mos</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 mos</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">84</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><300</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 mos</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3 hd_h_Metronidazole.Tf_1_1_1_4 hd_h_Metronidazole.Tf_1_1_1_5 hd_h_Metronidazole.Tf_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Metronidazole given for bacterial vaginitis</td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">~7 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11104</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">810</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12.2</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Protime index < 9%</td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">~10 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">~3 days</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20.5</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Liver transplant, post-operative death</td></tr><tr><td headers="hd_h_Metronidazole.Tf_1_1_1_1 hd_h_Metronidazole.Tf_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Metronidazole.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><42</b>
|
|
</td><td headers="hd_h_Metronidazole.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><300</b>
|
|
</td><td headers="hd_h_Metronidazole.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Metronidazole.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>*</dt><dd><div id="Metronidazole.TF.f.1"><p class="no_margin">Values estimated from Figure 1. Bilirubin results converted from mol to mg/dL (17.1) and enzyme results converted from kat to U/L (0.01667).</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobMetronidazoleTg"><div id="Metronidazole.Tg" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548609/table/Metronidazole.Tg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metronidazole.Tg_lrgtbl__"><table><tbody><tr><th id="hd_b_Metronidazole.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Metronidazole.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_b_Metronidazole.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Metronidazole.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Metronidazole.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metronidazole</td><td headers="hd_b_Metronidazole.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134974986" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">443-48-1</a>
|
|
</td><td headers="hd_b_Metronidazole.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C6-H9-N3-O3</td><td headers="hd_b_Metronidazole.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134974986" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134974986" alt="image 134974986 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|